Sanofi traded at 76.00 this Monday March 9th, decreasing 0.39 or 0.51 percent since the previous trading session. Looking back, over the last four weeks, Sanofi lost 7.54 percent. Over the last 12 months, its price fell by 30.58 percent. Looking ahead, we forecast Sanofi to be priced at 74.40 by the end of this quarter and at 68.72 in one year, according to Trading Economics global macro models projections and analysts expectations.
Sanofi SA is a healthcare company based in France. The Company focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme, among others.